Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445351 | 0.90 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL13894709 | 0.90 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL933535 | 0.87 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL1503531 | 0.86 | PKM (0.56) | L3MBTL1CTNNB1POLBALDH1A1RAB9A | |
| SCHEMBL657699 | 0.85 | L3MBTL1 (0.66) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL8421294 | 0.85 | PARP10 (0.59) | CTNNB1MAPTALDH1A1MAOB | |
| SCHEMBL1503528 | 0.85 | MAPT (0.69) | L3MBTL1GAACTNNB1MAPTLMNA | |
| SCHEMBL12691656 | 0.85 | CTNNB1 (0.52) | L3MBTL1GAACTNNB1MAPTRAB9A | |
| SCHEMBL21169051 | 0.85 | L3MBTL1 (0.61) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL19337421 | 0.83 | CTNNB1 (0.57) | L3MBTL1GAACTNNB1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-6603046-B1 | The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. | LICA PHARMACEUTICALS A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| EP-0634927-B1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | LICA PHARMACEUTICALS AS (DK) | 2001-07-04 | — | — | EP | disclosed |
| US-5985935-A | PARASITICIDES OR BACTERICIDES | STATENS SERUMINSTITUT (DK) | 1999-11-16 | — | — | US | disclosed |
| US-5420275-A | Chemiluminescent assay, tumors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0634927-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993017671-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1993-09-16 | — | — | WO | disclosed |
| EP-0491477-A1 | Pyridopyridazine compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1992-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | L3MBTL1 2810/4885GAA 116/4885CTNNB1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.